ISCHEMIA Trial and the Significance of MI
During the past decade, the treatment of choice for chronic coronary syndromes (CCS) has been a contentious issue. Whether revascularisation, either percutaneous or surgical, or optimal medical therapy, offers better prognosis in terms of mortality, MI, and symptom relief, has yet to be confirmed. T...
Guardado en:
Autores principales: | Eduardo A Arias, Félix Damas-de los Santos, Heriberto Ontiveros-Mercado |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/27f8c08c55f44a4e92f157da82c56f8d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cardioprotection for Acute MI in Light of the CONDI2/ERIC-PPCI Trial: New Targets Needed
por: Joel P Giblett, et al.
Publicado: (2020) -
Clinical significance of hsCRP level in acute coronary syndrome
por: V.K. Katyal, et al.
Publicado: (2021) -
Reprising an old friend – The Athens QRS score as a predictor of coronary artery disease in patients with intermediate treadmill test during ischemia evaluation
por: Prayaag Kini, et al.
Publicado: (2021) -
A study of immediate and long-term results of significant tricuspiud regurgitation after percutaneous mitral balloon valvotomy
por: Remala Archana, et al.
Publicado: (2021) -
Clinical profile of patients with qRBBB MI at tertiary care centre
por: Achal Sharma, et al.
Publicado: (2021)